Heparin and control of bleeding complications during platelet glycoprotein IIb/IIIa receptor antagonist therapy during percutaneous coronary revascularization

Journal of Invasive Cardiology

Volumn 8, Issue SUPPL. B, 1996, Pages

  Lincoff, A Michael ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 29344463268     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961.
2. Topol EJ, Califf RM, Weisman HS, et al. for the EPIC Investigators. Reduction of clinical restenosis following coronary intervention with early administration of platelet IIb/IIIa integrelin blocking antibody. Lancet 1994;343:881-886.
3. American College of Physicians Clinical Guideline. Practice strategies for elective red blood cell transfusion. Ann Int Med 1992;116:403-406.
4. Boehrer JD, Kereiakes DJ, Navetta FI, Califf RM, Topol EJ, for the EPIC investigators. Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. Am J Cardiol 1994;74:1166-1170.
5. Uthoff K, Zehr KJ, Geerling BA, et al. Inhibition of platelet adhesion during cardiopulmonary bypass reduces postoperative bleeding. Circulation 1994;90:II-269-II-274.
6. Aguirre PV, Topol EJ, Ferguson JJ, et al. for the EPIC Investigators. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation 1995;91:2882-2890.
7. Harrington RA, Marchant K, Kleiman NS, et al. Bleeding associated with use of a platelet glycoprotein IIb/IIIa inhibitor during routine coronary angioplasty: Is too much heparin the culprit (Abstr)? J Am Coll Cardiol 1994;23:106A.
8. Theroux P, Kouz S, Knudtson ML, et al. A randomized double-blind controlled trial with the non-peptide platelet GP IIb/IIIa antagonist Ro-44-9983 in unstable angina (Abstr). Circulation 1994;90:I-232.
9. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
10. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988;319:1105-1111.
11. RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990;336:827-830.
12. Holdright D, Patel D, Cunningham D, et al. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. J Am Coll Cardiol 1994;24:39-45.
13. Schwartz L, Bourassa MG, Lesperance J, et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988;318:1714-1719.
14. Barnathan ES, Schwartz JS, Taylor L, et al. Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation 1987;76:125-134.
15. Laskey MA, Deutsch E, Hirshfeld JWJ, et al. Influence of heparin therapy on percutaneous transluminal coronary angioplasty outcome in patients with coronary arterial thrombus. Am J Cardiol 1990;65:179-182.
16. Laskey MA, Deutsch E, Barnathan E, W.K. L. Influence of heparin therapy on percutaneous transluminal coronary angioplasty outcome in unstable angina pectoris. Am J Cardiol 1990;65:1425-1429.
17. Dougherty KG, Gaos CM, Bush HS, et al. Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin. Cathet Cardiovasc Diagn 1992;26:260-263.
18. Narins CR, Hillegass WB, Nelson CL, et al. Activated clotting time predicts abrupt closure risk during angioplasty (Abstr). J Am Coll Cardiol 1994;23:470A.
19. McGarry TF, Gottlieb RS, Morganroth J, et al. The relationship of anticoagulation level and complications after successful percutaneous transluminal coronary angioplasty. Am Heart J 1992;123:1445-1451.
20. Ellis SG, Roubin GS, Wilentz J, et al. Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. Am Heart J 1989;117:777-782.